NCT05053607: Real World Insights During Treatment for Relapsed/Refractory Myeloma With Isatuximab

NCT05053607: Real World Insights During Treatment for Relapsed/Refractory Multiple Myeloma With Isatuximab

NCT05053607: Real World Insights During Treatment for Relapsed/Refractory Multiple Myeloma With Isatuximab

This descriptive study aims to evaluate the experience of adults with relapsed or refractory multiple myeloma receiving standard of care isatuximab-irfc through collection of quantitative, qualitative and wearable data.

Sponsor

Pack Health

Collaborators

M.D. Anderson Cancer Center

Sanofi

---

ClinicalTrials.gov Identifier: NCT05053607

Official Title: Clinical and Patient Reported Outcomes for Individuals With Relapsed/Refractory Multiple Myeloma Treated With Isatuximab: Real-World Insights From Patient Reported, Wearable, and Qualitative Data in the Context of Digital Health Coaching

First Posted : September 22, 2021

Click here for details on ClinicalTrials.gov

---

Behavioral: Digital Health Coaching Program

Device: Fitbit

---

- Texas: The University of Texas MD Anderson Cancer Center Houston

---

Location

United States, Texas